๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer

โœ Scribed by G. T. Budd; R. M. Bukowski; A. Lichtin; L. Bauer; P. Kirk; R. Ganapathi

Publisher
Springer US
Year
1993
Tongue
English
Weight
361 KB
Volume
11
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of carboplatin and etopos
Phase II trial of carboplatin and etoposide in metastatic breast cancer
โœ John Crown; Thomas Hakes; Bonnie Reichman; David Lebwohl; Theresa Gilewski; Anto ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 345 KB ๐Ÿ‘ 2 views

## Background: High-dose chemotherapy with hematopoietic support produces high rates of response in metastatic breast cancer. to facilitate new high-dose regimens there is a need to identify active agents with toxicity limited to hematopoietic suppression. cisplatin/etoposide is a highly active reg

Methotrexate, vinblastine, doxorubicin,
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group
โœ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 490 KB ๐Ÿ‘ 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp